Better Health for All

Abeona Therapeutics' core business is developing gene and cell therapies for serious rare genetic diseases, with its product ZEVASKYN being the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).

Clinical studies showed 81% of ZEVASKYN-treated wounds achieved 50% or more healing at 6 months, compared to 16% in control wounds, with long-term improvement observed over a median of 6.9 years. All of the company's R&D expenses, which were $34.4 million in 2024, are dedicated to developing these health-improving therapies. The company does not report revenue from harmful products. Regarding safety, clinical trials for ZEVASKYN reported no treatment-related serious adverse events. Adverse events such as procedural pain and itch were observed in fewer than 5% of patients. The company demonstrates risk transparency by working with the FDA on product labeling and explicitly disclosing potential serious risks like allergic reactions, anaphylaxis, potential for cancer development, and infection risks in public information. Conversely, the company's focus is exclusively on treating existing conditions, with no reported investment in preventative health measures. Abeona obtained two new patents for ZEVASKYN, extending patent protection to 2037 and 2040. While a patient support program (Abeona Assist™) exists to help with insurance, financial assistance, travel, and logistics, there is no specific data on pricing accessibility, reach to vulnerable populations, or programs explicitly addressing health disparities. No information is provided regarding the ethical conduct of clinical trials.

Fair Money & Economic Opportunity

Abeona Therapeutics Inc. is a biopharmaceutical company focused on developing gene and cell therapies, not a financial institution. The provided articles discuss its FDA approval of ZEVASKYN

, product launch , patient support for navigating medical treatment costs (e.g., insurance and financial assistance for the drug) , and financial performance related to its core biopharmaceutical business. There is no evidence in the articles to suggest that the company offers lending, deposit, or other financial services to consumers. Therefore, all KPIs related to financial products, pricing, fees, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy programs, debt burden, geographic inclusion for financial services, or product simplicity for financial products are not applicable to its core business model.

Fair Pay & Worker Respect

Abeona Therapeutics received an overall employee rating of 1.7 out of 5 stars on Indeed.com, which translates to approximately 34% for employee engagement, indicating moderate discontent.

Employee reviews highlight concerns such as management disregarding company policy and guidelines, inconsistent remote work policies, and suggestions of unsafe situations where coworkers were taken advantage of, potentially impacting mental health. Additionally, the company incurred one substantiated workplace safety or health violation in 2022, resulting in a penalty of $18,053.

Fair Trade & Ethical Sourcing

No specific quantitative data related to fair trade, ethical sourcing, or supplier diversity is provided in the available articles for Abeona Therapeutics Inc.

While the company's Code of Conduct and Ethics outlines ethical standards, including ethical sourcing for business partners, these documents do not contain measurable data on certification share, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage, high-risk materials spend, or supplier diversity spend.

Honest & Fair Business

The company has a Code of Business Conduct and Ethics and a Compliance Helpline Policy.

An investigation into potential securities fraud or other unlawful business practices was initiated by Pomerantz LLP following an FDA Complete Response Letter (CRL) for a Biologics License Application (BLA) due to deficiencies in Chemistry Manufacturing and Controls (CMC) requirements. This CRL was announced on April 22, 2024, and led to a 53.67% drop in the company's stock price, falling $3.95 per share to $3.41 per share on April 23, 2024. The company files various SEC reports, including 10-K, 10-Q, 8-K, DEF 14A, ARS, and NT 10-K, with filings available from 1995 to 2026. Its most recent annual report is from 2024, with older reports available back to 2014.

Kind to Animals

Abeona Therapeutics Inc. uses animal testing in its product development, including preclinical eye programs

, safety studies in animal models for Sanfilippo syndrome (ABO-101 and ABO-102 ), and testing of novel AAV capsids in non-human primates . The company is listed on the Cruelty Free Investing animal use list due to its animal testing . There is no evidence that any of its products are certified cruelty-free . Furthermore, there is no indication that the company employs non-animal testing methods for product safety and efficacy , nor is there any mention of a formal policy to reduce, refine, or replace animal testing .

No War, No Weapons

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for serious diseases. The provided articles, which detail financial results, operational updates, and governance documents, explicitly state that no data is available or relevant to any of the 'No War, No Weapons' criteria

, , , , , , , . The company's core business activities, such as the commercial launch of ZEVASKYN for recessive dystrophic epidermolysis bullosa (RDEB) , and research and development in gene therapies, are entirely unrelated to arms manufacturing, military contracts, or conflict facilitation. Therefore, no KPIs related to this value can be scored based on the provided evidence.

Planet-Friendly Business

Sustainability data for Abeona Therapeutics Inc. (ABEO.US) is currently unavailable across multiple sources. No responsibility reports, sustainability reports, or similar documents are accessible.

While an aggregated ESG score for 'Environment' is reported as -1.03, and specific environmental sub-scores like 'GHG Emissions' (-0.31), 'Non-GHG Emissions' (-0.11), 'Scarce Natural Resources' (-0.06), 'Biodiversity' (-0.09), and 'Waste' (-0.46) are provided, these are composite scores and do not provide the specific quantitative metrics (e.g., total emissions in tCO₂e, percentage of renewable energy, waste diversion rates) required to assess against the detailed rubric KPIs.

Respect for Cultures & Communities

Abeona Therapeutics provides a Compliance Hotline, operated by an independent third-party vendor, available 24/7 via telephone and an online webpage for anonymous reports.

The company has 10 formal partnerships, including Nationwide Children's Hospital, DEBRA of America, Ultragenyx, Taysha Gene Therapies, and seven international patient advocacy groups. No cultural appropriation incidents have been reported. The company's operations do not require a specific cultural impact assessment protocol, Free, Prior, and Informed Consent (FPIC) processes, or specific cultural preservation funding. There is no specific community representation on governance bodies, no reported cultural site disruptions, and no cultural incident response framework is mentioned.

Safe & Smart Tech

Abeona Therapeutics Inc. has not identified any material cybersecurity incidents or unauthorized data use incidents.

The company's cybersecurity program is developed following the National Institute of Standards and Technology (NIST) framework. It conducts periodic penetration and vulnerability testing, as well as data recovery testing. Cybersecurity training is provided to employees, and an ongoing information security training program is being formalized for active employees and relevant consultants to address matters such as phishing, email security, social engineering, and data privacy. The company states compliance with applicable laws and regulations, including COPPA, GDPR, CCPA, CPRA, HIPAA, and the U.S. Foreign Corrupt Practices Act, and maintains a corporate compliance program. Users have choices regarding cookies and can request deletion or modification of their data; California and Virginia residents have specific rights, and a multi-factor authentication process is used to confirm identity for data requests. The company retains information only as long as reasonably necessary for stated purposes and in accordance with applicable laws.

Zero Waste & Sustainable Products

No specific data is available regarding Abeona Therapeutics Inc.'s waste management, sustainable products, or circular economy initiatives. The provided articles indicate a complete absence of data on sustainability metrics, including waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, or supplier/customer waste requirements.

While a 'Negative Waste Score' of -0.46 is mentioned, it lacks the specific context or quantitative detail required to map to any of the defined KPIs.